PDCD1 and neoplasm: However, analysis of CT26 tumor-infiltrating immune cells demonstrated a significant decrease in regulatory T cells (CD3+; CD4+; FOXP3+) when RXC004 was combined with anti-PD-1 treatment over control or either monotherapy.